InterStim Therapy System, Verify Evaluation System
Medtronic Neuromodulation · Decision date Oct 9, 2026
What did the FDA decide?
The FDA record P970004/S459, decided 2026-10-09 as OK30 under a 30-Day Notice for a process change involving a manufacturer, sterilizer, packager, or supplier, covers the InterStim Therapy System and Verify Evaluation System. The stated purpose is approval to introduce a second Medium Rate (MR) Header manufacturing line, MR Line 2, and to make inspection updates to the MR Headers Line currently in production at Medtronic Energy and Components Center (MECC), Brooklyn Center, MN. The applicant is Medtronic Neuromodulation; the device category is an electrical implantable stimulator for incontinence, product code EZW.
This is a supplement to PMA P970004, not a new approval of the whole system, and the notice concerns manufacturing and inspection at one site. The record does not describe header specifications, the inspection changes, validation data, or any clinical or safety finding; the stated purpose alone does not establish safety or effectiveness.
FDA approval order statement
approval for the introduction of a second Medium Rate (MR) Headers manufacturing line (MR Line 2) and to make inspection updates to the MR Headers Line that is currently in production at Medtronic Energy and Components Center (MECC), Brooklyn Center, MN.
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Gastroenterology, Urology
- Decision date
- Oct 9, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P970004/S459
- Regulatory pathway
- PMA supplement
- Applicant
- Medtronic Neuromodulation
- Product code
- EZW
- Decision code
- OK30
- Decision date
- Oct 9, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Stimulator, electrical, implantable, for incontinence.
- Applicant
- Medtronic Neuromodulation
- Product code
- EZW
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P970004. Subsequent supplements may change the device or its indications.
FDA decision timeline
P970004 · Original PMA
MEDTRONIC INTERSTIM THERAPY SYSTEM FOR URINARY CONTROL
P970004/S459 received
Application receipt date recorded by FDA.
P970004/S458 · Related supplement
InterStim Therapy System Verify Evaluation System
P970004/S457 · Related supplement
InterStim Therapy System, Verify Evaluation System
P970004/S459 · FDA decision
30-Day Notice
P970004/S460 · Related supplement
InterStim Therapy System, Verify Evaluation System (SNS Urinary Neurostimulator 97800), (SNS Urinary Neurostimulator I
Timeline entries are records held by MedtechLedger for P970004. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P970004
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Medtronic Neuromodulation | PMA approval | Sep 29, 1997 | FDA | |
| Medtronic Neuromodulation | PMA supplement | Sep 14, 2026 | FDA | |
| Medtronic Neuromodulation | PMA supplement | Oct 6, 2026 | FDA | |
| Medtronic Neuromodulation | PMA supplement | Oct 29, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Medtronic Neuromodulation
- Headquarters
- Not reported
- Brand website
- medtronic.com
- FDA applicant address
- 7000 Central Ave., NE, Minneapolis, MN, 55432
Sources and methodology
- Original FDA record: P970004/S459
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


